New York, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Vascular Grafts Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05995083/?utm_source=GNW


The global vascular graft market is expected to decline from $2.79 billion in 2019 to $2.6 billion in 2020 at a compound annual growth rate (CAGR) of -6.98%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $3.27 billion in 2023 at a CAGR of 8.02%.

The vascular graft global market consists of sales of vascular grafts and related services by entities (organizations, sole traders and partnerships) that manufacture vascular grafts that are used to repair the diseased or blocked blood vessel during the surgical procedure called vascular grafting or vascular bypass. Vascular grafting is performed to bypass a partial or complete blockage in an artery by reconnecting the blood vessels. This process will improve the blood flow by redirecting blood from one area of the body to another. Vascular grafts are mainly used in the heart during coronary artery bypass and in legs to treat vascular disease.

North America was the largest region in the vascular graft market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

In November 2019, Terumo Aortic acquired Aortica Corporation for an undisclosed amount. The acquisition is expected to expand Terumo Aortic’s product portfolio by adding the fenestrated endovascular aortic repair (FEVAR) system to its product options. Aortica Corporation is a US-based company involved in the designing, manufacturing, and marketing of tools used for the treatment of patients suffering from abdominal aortic aneurysms (AAA) disease.

The vascular graft market covered in this report is segmented by product into hemodialysis access graft; endovascular stent graft; peripheral vascular graft; coronary artery by-pass graft, by raw material into polyester grafts; EPTFE; polyurethane grafts; biosynthetic grafts, by application into coronary artery disease; aneurysm; vascular occlusion; renal failure, and by end-user into hospitals; ambulatory surgical centers.

The high cost of medical treatment and complications related to prosthetic grafts are expected to restrain global vascular grafts market growth. The cost of the CABG (coronary artery bypass graft) surgery is very high in western countries. For instance, in the US, the average cost of coronary artery bypass surgery is $40,000, which varies widely by region and facility. Moreover, several complications are associated with prosthetic grafts such as disruption of an infected anastomotic suture line due to rupture or pseudoaneurysm formation, sepsis, amputation, thromboembolism, chances of reinfection due to vascular grafts reconstruct, enteric fistulae, the spread of bacterial infection to other sites, and death. Thus, high treatment costs and complications related to prosthetic grafts are expected to restrain market growth.

Companies in the vascular graft market are increasingly investing in technological advances for the development of innovative vascular grafts, including customization of vascular grafts. For instance, RelayPro, a thoracic stent graft system recently launched by Terumo Aortic, is a low-profile device designed for patients with smaller access vessels in the treatment of thoracic endovascular aortic repair (TEVAR). It offers a broad range of diameters, lengths, tapers, and proximal configurations to the physicians. Both bare stent and non-bare stent (NBS) versions are available for this device and it can be customized to meet the patient’s specific anatomical needs.

The rising prevalence of vascular diseases is driving the growth of the global vascular grafts market. According to a study by the National Center for Biotechnology Information in the US, cardiovascular diseases are the leading cause of death in the world and according to the American Heart Association(AHA), in 2018, the overall prevalence of myocardial infarction in the US was around 7.9 million per year, while the estimated annual incidence of a heart attack in the US is 720,000 new attacks and 335,000 recurrent attacks. According to a study by NHS Inform, a national health service of Scotland, every year around 20,000 coronary bypass grafts are carried out in England. Therefore, the high prevalence of vascular diseases is anticipated to drive the global vascular grafts market.




Read the full report: https://www.reportlinker.com/p05995083/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001